Preterm Birth And PROM Testing Industry Overview
The global preterm birth and PROM testing market size is expected to reach USD 1.9 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 3.0% from 2021 to 2028. Key factors that can be attributed to market growth are rising number of preterm births in developed and emerging economies, improving access to advanced neonatal and maternal care facilities, and introduction of new POC diagnostic products over the forecast period.
Preterm births are not specific to a particular geography and have been recognized as a worldwide concern. The risk of preterm births typically escalates with increasing average age of pregnant women. With growing awareness about preterm births and its consequence, the tendency of pregnant women to enroll for Premature Rupture of Membranes (PROM) testing during their pregnancy is anticipated to increase, for reassurance and monitoring of symptoms of preterm birth.
Point-of-Care (POC) diagnostics have drastically altered the methodology of testing in various fields. With the help of advanced technology, devices are able to assess analyte in a given sample. Companies are focusing on R&D to increase specificity and sensitivity of devices, which lowers the error rate. Hence, emphasis is being given to reducing sample size required for other medical testing.
Preterm Birth And PROM Testing Market Segmentation
Grand View Research has segmented the global preterm birth and PROM testing market on the basis of test type and region:
Based on the Type Insights, the market is segmented into Pelvic exam, Ultrasound, Biochemical Markers, Uterine Monitoring, Nitazine Test, Ferning Test, Pooling, PAMG-1 Immunoassay, IGFBP Test, Fetal Fibronectin (fFN), Others.
The ultrasound segment dominated the market and accounted for the largest revenue share of 31.9% in 2020.
Ultrasound imaging is one of the traditional methods of testing preterm labor. Doctors often perform an ultrasound to create images of the uterus and the baby to determine if the cervix has dilated or effaced, thus, leading to high adoption rate.
The Insulin-like Growth Factor Binding Protein 1 (IGFBP-1) test segment is anticipated to grow at 3.4% in the market over the forecast period. This can be attributed to the fact that (IGFBP-1) or placental protein 12 is an important protein biomarker for PROM testing.
High levels of the protein in vaginal fluid indicate a rupture of the amniotic sac, wherein protein is present in higher concentration compared to serum, urine, and cervical mucus.
PREMAQUICK, by BIOSYNEX, is an IGFBP-1 biomarker test that helps in predicting preterm birth in 7 days with 87.1% sensitivity, 95% accuracy, and 92.4% specificity.
Preterm Birth And PROM Testing Regional Outlook
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Companies Profile & Market Share Insights
The market is highly competitive with presence of many global and local players. The major companies are involved in adopting different growth strategies such as new product development, product differentiation strategies, and expansion of geographical reach in an attempt to capture large share of the market.
Some prominent players in the global preterm birth and PROM testing market include
Qiagen N.V.
Hologic, Inc.
Cooper Surgical Inc.
Abbott
Medixbiochemica
Sera prognostics
Clinical Innovations, LLC
Biosynex
NX Prenatal, Inc.
IQ Products
Order a free sample PDF of the Preterm Birth And PROM Testing Market Intelligence Study, published by Grand View Research.
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com